Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dialysis01:27

Dialysis

235
Renal failure occurs when the kidneys lose their ability to filter waste products from the blood effectively. It can be classified into two types: acute renal failure (ARF) and chronic renal failure (CRF).
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
235
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

60
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
60
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

92
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
92
Cancer Survival Analysis01:21

Cancer Survival Analysis

308
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
308
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

106
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
106
Actuarial Approach01:20

Actuarial Approach

49
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
49

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A sustainable future for peritoneal dialysis: a patient survey on green nephrology.

Journal of nephrology·2026
Same author

Correction: Home-based Rehabilitation With A Novel Digital Biofeedback System versus Conventional In-person Rehabilitation after Total Knee Replacement: a feasibility study.

Scientific reports·2026
Same author

Long-term renal function and complication profiles after ABO-incompatible <i>vs</i> compatible living-donor kidney transplantation: A single-center experience.

World journal of transplantation·2026
Same author

Proteinuria remission profiles in obesity-related kidney disease after bariatric surgery.

American journal of physiology. Renal physiology·2026
Same author

A strategic discovery roadmap towards high-quality leads and drug development candidates for kinetoplastid diseases. Part 3: from lead towards a drug development candidate.

The Journal of antimicrobial chemotherapy·2026
Same author

A strategic discovery roadmap towards high-quality leads and drug development candidates for kinetoplastid diseases. Part 1: setting the stage.

The Journal of antimicrobial chemotherapy·2026

Related Experiment Video

Updated: May 15, 2025

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.0K

Insights Into Peritoneal Dialysis Outcomes: An Approach Using Competing Risks Analysis.

Ana Cunha1, Beatriz Gil Braga1, Sofia Sousa2

  • 1Department of Nephrology, Centro Hospitalar Universitário de Santo António, Unidade Local de Saúde de Santo António, Porto, Portugal.

Seminars in Dialysis
|April 15, 2025
PubMed
Summary
This summary is machine-generated.

The main risk for peritoneal dialysis (PD) patients is transitioning to hemodialysis (HD), which is not influenced by baseline characteristics. Choosing PD-first positively impacts kidney transplant (KT) access and maintains low mortality rates.

Keywords:
competing risks analysisperitoneal dialysistransfer to hemodialysis

More Related Videos

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.0K
A Retrograde Implantation Approach for Peritoneal Dialysis Catheter Placement in Mice
06:27

A Retrograde Implantation Approach for Peritoneal Dialysis Catheter Placement in Mice

Published on: July 20, 2022

2.5K

Related Experiment Videos

Last Updated: May 15, 2025

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.0K
Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.0K
A Retrograde Implantation Approach for Peritoneal Dialysis Catheter Placement in Mice
06:27

A Retrograde Implantation Approach for Peritoneal Dialysis Catheter Placement in Mice

Published on: July 20, 2022

2.5K

Area of Science:

  • Nephrology
  • Clinical Epidemiology

Background:

  • Peritoneal dialysis (PD) outcomes are complex due to varied results.
  • Analyzing PD patient outcomes requires understanding factors influencing mortality, transition to hemodialysis (HD), and kidney transplantation (KT).

Purpose of the Study:

  • To evaluate mortality, HD transfer, and KT rates in PD patients.
  • To identify baseline patient characteristics affecting these PD outcomes.

Main Methods:

  • Observational, retrospective, registry-based, single-center cohort study.
  • Included 722 incident adult PD patients (1985-2022).
  • Used competitive risks analysis (cumulative incidence functions, Fine and Gray model).

Main Results:

  • The highest probability at 60 months was transfer to HD (0.38), followed by KT (0.27) and death (0.19).
  • Diabetes correlated with increased mortality (HR 1.71).
  • PD-first approach reduced HD transfer risk (HR 0.76) and increased KT likelihood (HR 1.73).
  • Vascular access as PD reason linked to higher mortality (HR 2.16).

Conclusions:

  • Transition to HD is the primary risk for PD patients, independent of baseline factors.
  • A PD-first strategy enhances KT access and ensures low, unaffected mortality rates, confirming PD safety.
  • Vascular access-driven PD initiation is associated with increased mortality, possibly due to comorbidities.